Business Context and Reporting Period
Company: Artiva Biotherapeutics, Inc. (ARTV)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Artiva is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company's lead product candidate, AlloNK (AB-101), is in early clinical development for indications including systemic lupus erythematosus (SLE), lupus nephritis (LN), and rheumatoid arthritis (RA). The company has no products approved for commercial sale and has not generated revenue from product sales.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0.3 million (License/Development Support) |
| Net Loss | $(41.6) million | $(31.8) million |
| Net Loss Per Share (Basic & Diluted) | $(1.71) | $(39.24) |
| Operating Expenses | $45.0 million | $30.9 million |
| Research & Development (R&D) | $34.9 million | $23.5 million |
| General & Administrative (G&A) | $10.1 million | $7.4 million |
| Cash, Cash Equivalents & Investments | $142.4 million | $185.4 million (Dec 31, 2024) |
| Accumulated Deficit | $(288.2) million | $(246.7) million (Dec 31, 2024) |
| Net Cash Used in Operating Activities | $(42.8) million | $(28.8) million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $9.8 million (31%) compared to the prior year period, driven primarily by higher operating expenses.
- R&D Expense Growth: R&D expenses increased by $11.4 million, primarily due to an $8.4 million increase in external costs related to the development and ongoing clinical trials of AlloNK in autoimmune diseases.
- G&A Expense Growth: G&A expenses increased by $2.6 million, largely due to increased personnel-related costs and stock-based compensation associated with operating as a public company.
- Revenue Cessation: The company recognized $0 in license and development support revenue for the six months ended June 30, 2025, compared to $0.3 million in the prior year period.
- Interest Income: Interest income increased by $2.1 million to $3.4 million due to higher investment balances.
- SAFE Fair Value: The change in fair value of Simple Agreements for Future Equity (SAFEs) was $0 in the current period, compared to a $2.6 million loss in the prior year period (SAFEs converted to common stock upon the July 2024 IPO).
Guidance, Outlook, and Risks
Outlook and Liquidity: Management expects to continue incurring significant losses for the foreseeable future. As of June 30, 2025, the company had $142.4 million in cash, cash equivalents, and investments. Management believes these funds are sufficient to fund planned operations into the second quarter of 2027. The company anticipates reporting initial safety and translational data for AlloNK in combination with a monoclonal antibody across multiple autoimmune indications by the end of 2025.
Recent Developments:
- Clinical Progress: Initiated a global Phase 2a company-sponsored basket clinical trial for AlloNK in combination with rituximab for refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis. Treated the first patient in this trial in August 2025.
- Collaboration Termination: Terminated the collaboration agreement with Affimed GmbH in July 2025 following Affimed's insolvency filing in May 2025. No fees were payable or receivable due to termination.
- Strategic Shift: Completed the Phase 1/2 clinical trial of AlloNK in combination with rituximab for B-cell non-Hodgkin lymphoma (B-NHL) in July 2025 and discontinued long-term follow-up to focus resources on autoimmune indications.
Key Risks:
- Capital Requirements: The company will need substantial additional funding to complete development and commercialization. Failure to raise capital could force delays or elimination of R&D programs.
- Unproven Technology: The approach to developing NK cell-based therapies for autoimmune diseases is novel and unproven. No cell therapy is currently approved for autoimmune diseases.
- Manufacturing Reliance: The company relies on third-party manufacturers, including GC Cell, for product supply. Disruptions could delay clinical trials.
- Regulatory Uncertainty: Regulatory pathways for cell therapies are evolving, and approval is not guaranteed.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $142.4 million cash balance against the projected burn rate to confirm the "into Q2 2027" liquidity estimate.
- Clinical Trial Enrollment: Monitor enrollment rates and safety data readouts for the Phase 2a basket trial in autoimmune indications, as this is the primary near-term catalyst.
- Manufacturing Capacity: Assess the status of the company's own clinical manufacturing facility in San Diego and the reliance on GC Cell for supply continuity.
- Collaboration Pipeline: Evaluate the impact of the Affimed termination on the company's strategic partnerships and potential future revenue streams.
- Regulatory Status: Track FDA feedback on the Phase 2a trial design and any potential clinical holds or safety concerns.